公开(公告)号：US20250109179A1

公开(公告)日：2025-04-03

申请号：US18811531

申请日：2024-08-21

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Dianne S. Sako ,  Roselyne Castonguay ,  Tzu-Hsing Kuo

IPC: C07K14/705 ,  A61K38/00 ,  C07K14/71 ,  C07K16/22

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:TβRII heteromultimers comprising an ActRIIA polypeptide and a TβRII polypeptide). The disclosure further provides that such multispecific binders (e.g., ActRIIA:TβRII heteromultimer) may be used to treat various disorders or conditions.

公开(公告)号：US12042524B2

公开(公告)日：2024-07-23

申请号：US17231981

申请日：2021-04-15

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Jonathan Belk ,  Asya Grinberg ,  Dianne Sako ,  Roselyne Castonguay

IPC: C07K16/28 ,  A61K38/02 ,  A61K38/16 ,  C07K14/00 ,  C07K14/47 ,  A61K38/00 ,  C07K5/00

CPC classification number: A61K38/02 ,  A61K38/16 ,  C07K14/001 ,  C07K14/47 ,  C07K16/2863 ,  A61K38/00 ,  C07K5/00 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/76 ,  C07K2317/92

Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated musle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.

公开(公告)号：US12024563B2

公开(公告)日：2024-07-02

申请号：US17505124

申请日：2021-10-19

Applicant: Acceleron Pharma Inc.

Inventor： John Knopf ,  Ravindra Kumar ,  Asya Grinberg ,  Robert Scott Pearsall ,  Dianne S. Sako ,  Roselyne Castonguay ,  Gang Li ,  Yossi Dagon

IPC: A61K38/17 ,  C07K14/71 ,  C07K16/28 ,  C12N9/12

CPC classification number: C07K16/2863 ,  A61K38/1709 ,  A61K38/177 ,  C07K14/71 ,  C12N9/1205 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/10 ,  C07K2319/20 ,  C07K2319/30 ,  C07K2319/35 ,  C07K2319/70 ,  C07K2319/74

Abstract: In certain aspects, the disclosure provides ALK7 antagonists. In certain aspects, these ALK7 antagonists are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof. In certain aspects, these ALK7 antagonists can be used to treat or prevent cancer.

公开(公告)号：US11981738B2

公开(公告)日：2024-05-14

申请号：US16757959

申请日：2018-10-25

Applicant: Acceleron Pharma Inc. ,  Adimab, LLC

Inventor： Ravindra Kumar ,  Roselyne Castonguay ,  Dianne Sako ,  Jonathan Belk ,  Nathan J. Sharkey

IPC: A61K39/395 ,  A61P3/06 ,  C07K16/28 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A61P3/06 ,  A61K2039/505 ,  C07K2317/34 ,  C07K2317/92

Abstract: The disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments, the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, obesity, type 2 diabetes, and their associated conditions, metabolic disorders, and other diseases or conditions that can be treated by targeting ALK7.

公开(公告)号：US11951156B2

公开(公告)日：2024-04-09

申请号：US16851287

申请日：2020-04-17

Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC. ,  ACCELERON PHARMA, INC.

Inventor： Paul B. Yu ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay ,  Rita Steeves ,  Ravindra Kumar

IPC: A61K38/17 ,  A61K47/68 ,  A61P9/12 ,  A61P11/00 ,  C07K14/71 ,  C07K19/00

CPC classification number: A61K38/179 ,  A61K47/6811 ,  A61P9/12 ,  C07K14/71 ,  C07K19/00 ,  C07K2319/30 ,  C07K2319/32

Abstract: In some aspects, the invention teaches pharmaceutical compositions that include a TGF-β ligand trap, and methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of pulmonary hypertension (PH). The invention also provides methods of using a TGF-β ligand trap to treat, prevent, or reduce the progression rate of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, right ventricular hypertrophy, diseases associated with excessive TGF-β signaling, diseases associated with excessive GDF15 signaling, and diseases associated with excessive PAI-1 signaling. The invention further provides methods of using a TGF-β ligand trap to reduce right ventricular systolic pressure in a subject.

公开(公告)号：US20230190875A1

公开(公告)日：2023-06-22

申请号：US17784029

申请日：2020-12-09

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Gang Li

IPC: A61K38/17 ,  A61P9/12 ,  A61K45/06

CPC classification number: A61K38/179 ,  A61K38/1796 ,  A61K45/06 ,  A61P9/12

Abstract: In some aspects, the disclosure relates to single-arm ActRIIA heteromultimers and single-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using single-arm ActRIIA heteromultimers and single-arm ActRIIB heteromultimers to reduce right ventricular systolic pressure in a subject in need thereof.

公开(公告)号：US20230183319A1

公开(公告)日：2023-06-15

申请号：US17797238

申请日：2021-02-03

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Roselyne Castonguay ,  Brantley Herrin ,  Rose Maria Silva Garcia Grenha

IPC: C07K14/71 ,  A61K45/06 ,  A61K38/17 ,  A61P13/12 ,  A61P29/00

CPC classification number: C07K14/71 ,  A61K38/179 ,  A61K45/06 ,  A61P13/12 ,  A61P29/00 ,  C07K2319/30

Abstract: In certain aspects, the present invention provides novel ActRIIB variants (in a homomultimeric or heteromultimeric form), as well as compositions and methods for using those variants to treat an indication associated with undesired activity of one or more TGFβ-superfamily ligands. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

公开(公告)号：US20220372107A1

公开(公告)日：2022-11-24

申请号：US17052785

申请日：2019-05-02

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Dianne S. Sako ,  Roselyne Castonguay ,  Tzu-Hsing Kuo

IPC: C07K14/705 ,  C07K14/71 ,  C07K16/22

Abstract: In certain aspects, the disclosure provides multispecific binders (e.g., ActRIIA:TβRII heteromultimers comprising an ActRIIA polypeptide and a TfiRU polypeptide). The disclosure further provides that such multispecific binders (e.g., ActRIIA:TβRII heteromultimer) may be used to treat various disorders or conditions.

公开(公告)号：US11497792B2

公开(公告)日：2022-11-15

申请号：US16943289

申请日：2020-07-30

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg

IPC: A61K38/17 ,  A61K47/68 ,  A61K9/00 ,  A61P21/06 ,  C07K14/47 ,  C07K19/00 ,  A61K38/00

Abstract: The disclosure provides, in part, follistatin polypeptides that are suitable for use in local administration and methods for use.

公开(公告)号：US11440949B2

公开(公告)日：2022-09-13

申请号：US16340040

申请日：2017-10-05

Applicant: Acceleron Pharma Inc.

Inventor： Ravindra Kumar ,  Asya Grinberg ,  Dianne S. Sako ,  Roselyne Castonguay

IPC: C07K14/71 ,  A61K38/00

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK.6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells. In certain aspects, such soluble polypeptide complexes are can be used to improve muscle formation, bone formation, hematopoiesis, metabolic parameters, and disorders associated with these tissues, cellular networks, and endocrine systems.